A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan
NCT ID: NCT06635057
Last Updated: 2026-01-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE4
130 participants
INTERVENTIONAL
2024-10-11
2026-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes
NCT03882970
A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes
NCT05433584
A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2)
NCT05706506
A Study of Tirzepatide (LY3298176) in Healthy Participants and Participants With Type 2 Diabetes (T2DM)
NCT02759107
A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus
NCT04050553
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Tirzepatide
Participants will receive tirzepatide subcutaneously (SC)
Tirzepatide
Administered SC
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tirzepatide
Administered SC
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have HbA1c ≥7% within 30 days prior to screening
* Are glucagon-like peptide-1 receptor agonist (GLP-1 RA) naïve
* Have had stable body weight self-reported change ≤5 kilograms (kg) during the 90 days prior to screening
* Have body mass index ≥25 kilograms per square meter (kg/m2) at screening
Exclusion Criteria
* Have a history of chronic or acute pancreatitis
* Have acute or chronic hepatitis
* Have evidence of a significant, uncontrolled endocrine abnormality
* Have a history of an active or untreated malignancy
* Have New York Heart Association Functional Classification IV congestive heart failure
* Have been treated with insulin within two weeks prior to screening
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eli Lilly and Company
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Role: STUDY_DIRECTOR
Eli Lilly and Company
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
NMC Abu Dhabi
Abu Dhabi, , United Arab Emirates
Al Moosa Specialist Hospital
Al Ahasa, , Saudi Arabia
National Guard Hospital-King Abdulaziz Medical City
Alahsa, , Saudi Arabia
King Abdulaziz Medical City-Jeddah
Jeddah, , Saudi Arabia
King Fahad Armed Forces Hospital Jeddah
Jeddah, , Saudi Arabia
King Faisal Specialist Hospital & Research Center
Jeddah, , Saudi Arabia
Saudi Airlines Medical services
Jeddah, , Saudi Arabia
King Faisal Specialist Hospital and Research Center Madina
Madinah, , Saudi Arabia
King Saud University
Riyadh, , Saudi Arabia
Osepdale Fatebenefratelli e Oftalmico
Riyadh, , Saudi Arabia
Al Dallah Hospital
Riyadh, , Saudi Arabia
Sulaiman Habib Olaya
Riyadh, , Saudi Arabia
Specialized Medical Center Hospital
Riyadh, , Saudi Arabia
Dallah Namar Hospital
Riyadh, , Saudi Arabia
Dr. Sulaiman Al Habib Hospital As Suwaidi
Riyadh, , Saudi Arabia
Dr. Sulaiman Al Habib Medical Complex Arrayan Saudi Arabia
Riyadh, , Saudi Arabia
Lifecare Hospital
Abu Dhabi, , United Arab Emirates
Tawam Hospital
Abu Dhabi, , United Arab Emirates
Imperial College London Diabetes Center
Abu Dhabi, , United Arab Emirates
Rashid Centre for Diabetes and Research
Ajman, , United Arab Emirates
Thumbay University Hospital
Ajman, , United Arab Emirates
Emirates Hospital Dubai
Dubai, , United Arab Emirates
Aster Clinics
Dubai, , United Arab Emirates
Dubai Diabetes Center
Dubai, , United Arab Emirates
Dubai Hospital
Dubai, , United Arab Emirates
Medcare Hospital
Dubai, , United Arab Emirates
Mediclinic City Hospital
Dubai, , United Arab Emirates
Rashid Hospital.
Dubai, , United Arab Emirates
Medcare Hospital
Sharjah city, , United Arab Emirates
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
I8F-MC-GPIY
Identifier Type: OTHER
Identifier Source: secondary_id
27195
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.